BENEFIT APPLICATION
Subject to the terms and conditions of the applicable benefit contract, the AlloMap™ Molecular Expression Test for Heart Transplant Rejection is covered under the medical benefits of the Company's products when the medical necessity criteria listed in the medical policy are met.
US FOOD AND DRUG ADMINISTRATION STATUS
The AlloMap™ Molecular Expression Test for Heart Transplantation Rejection received FDA approval on August 27, 2008 as an In Vitro Diagnostic Multivariate Index Assay test.